At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 15 enrolled
Drug / intervention
nab-sirolimusdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/1b Clinical Trial of ABI-009, an mTOR Inhibitor, for Patients With Severe Pulmonary Arterial Hypertension (PAH)
In Brief
A Phase 1 clinical trial evaluating nab-sirolimus for Pulmonary Hypertension. Completed, enrolled 15 participants across 6 sites.
Detailed Summary
mTOR activation has been shown to be relevant in the development and progression of pulmonary hypertension. Inhibition of mTOR has been shown to reverse or regress pulmonary hypertension in animal models. nab-Sirolimus (also known as ABI-009, nab-rapamycin) is an albumin-bound mTOR inhibitor with improved penetration in lung tissue.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Hypertension
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 2015
Enrollment StartApr 2017
Primary CompletionAug 2022
Study CompletionSep 2022
TodayJul 2026
First PostedOct 27, 2015
Enrollment StartApr 1, 2017
Primary CompletionAug 16, 2022
Study CompletionSep 16, 2022
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 10.7 years ago
Interventions
nab-sirolimusdrug
nab-sirolimus is an mTOR inhibitor